Aberdeen Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Aberdeen Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$24.5M	Buy	439,715 +7,508	+2%	+$409K	0.08%	221
2017 Q1	$23.5M	Buy	432,207 +21,832	+5%	+$1.2M	0.08%	214
2016 Q4	$24M	Sell	410,375 -104,050	-20%	-$5.69M	0.09%	207
2016 Q3	$27.7M	Sell	514,425 -5,822	-1%	-$374K	0.1%	167
2016 Q2	$38.3M	Sell	520,247 -41,134	-7%	-$2.91M	0.14%	105
2016 Q1	$35.9M	Sell	561,381 -63,053	-10%	-$3.98M	0.13%	104
2015 Q4	$39.5M	Buy	624,434 +128,658	+26%	+$8.5M	0.13%	100
2015 Q3	$29.4M	Sell	495,776 -17,075	-3%	-$1.08M	0.1%	125
2015 Q2	$34.1M	Sell	512,851 -114,744	-18%	-$7.56M	0.1%	117
2015 Q1	$40.5M	Sell	627,595 -195,790	-24%	-$12.3M	0.11%	106
2014 Q4	$48.6M	Sell	823,385 -360,374	-30%	-$20.3M	0.12%	95
2014 Q3	$60.6M	Buy	1,183,759 +19,036	+2%	+$951K	0.13%	89
2014 Q2	$56.5M	Buy	1,164,723 +992,115	+575%	+$48.9M	0.12%	102
2014 Q1	$8.97M	Sell	172,608 -700	-0.4%	-$37.2K	0.03%	133
2013 Q4	$9.14M	Hold	173,308	–	–	0.03%	129
2013 Q3	$8.02M	Sell	173,308 -14,600	-8%	-$641K	0.02%	128
2013 Q2	$8.4M	Buy	+187,908	New	+$8.16M	0.03%	121

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aberdeen Asset Management's BMY Position: Q2 2017 in Review

Aberdeen Asset Management increased its Bristol-Myers Squibb (BMY) stake by 1.7% in Q2 2017, buying an estimated $409K and bringing the position to 439,715 shares worth $24.5M. The position accounts for 0.08% of the portfolio, ranked #221.

Aberdeen Asset Management first reported a position in BMY in Q2 2013 and has held it in 17 quarters since. The position peaked at $60.6M in Q3 2014. 1,595 funds tracked by Wall St. Rank hold BMY as of Q2 2017.

Aberdeen Asset Management held 439,715 shares of Bristol-Myers Squibb worth $24.5M as of Q2 2017.
Aberdeen Asset Management bought 7,508 Bristol-Myers Squibb shares in Q2 2017, an estimated $409K.
Bristol-Myers Squibb made up 0.08% of Aberdeen Asset Management's portfolio in Q2 2017, its #221 holding.
Aberdeen Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 17 quarters since.
Aberdeen Asset Management's Bristol-Myers Squibb position peaked at $60.6M in Q3 2014.
1,595 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.